Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.84) EPS for the quarter, Zacks reports.
Enzon Pharmaceuticals Stock Up 1.9%
ENZN traded up $0.12 during trading on Monday, hitting $6.50. The company’s stock had a trading volume of 159 shares, compared to its average volume of 1,162. The firm has a market capitalization of $4.81 million, a P/E ratio of -0.93 and a beta of -0.03. Enzon Pharmaceuticals has a twelve month low of $1.50 and a twelve month high of $12.99. The stock’s fifty day moving average price is $6.08 and its 200-day moving average price is $5.59.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Read More
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
